BioSpace News Archive

– New project seeks to expand on positive preliminary results from ongoing research program with McMaster University to develop innovative drug delivery systems using disruptive PGX Technology – Ceapro at the forefront of pioneering approaches with natural products through utilizing validated enabling technology

RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com ), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today announced that its Vice President, Scientific Affairs, Dr. Robin A. Robinson will now serve in a new and expanded full-time role as the Company’s Chief Scientific Officer. Prior to joining RenovaCare, Dr. Robinson served as founding Director of the Bio

Emmes today announced that its data and statistical analysis work for the Adaptive COVID-19 Treatment Trial (ACTT) played an important role in the accelerated timetable to evaluate remdesivir’s effectiveness in treating hospitalized CO

- Phase 2b ADVISE trial evaluating etrasimod in atopic dermatitis (AD) enrollment complete, meeting the high end of targeted enrollment range, topline data expected Q4 2020 - Etrasimod ELEVATE UC Program remains on track - Updated guidance for newly initiated trials, and certain trials in planning phase

DaVita Inc. (NYSE: DVA) (“DaVita”) announced today that it has commenced a private offering of $1.75 billion aggregate principal amount of senior notes due 2030 (the “2030 notes”), subject to market and other conditions. Prior to the closing date of this offering, DaVita will deliver a notice of conditional redemption to holders of its 5.1

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced that it received written communication from the U.S. Food and Drug Administration (FDA) that the clinical dev

-- Improvements in both serum liver enzymes and liver imaging -- Improvement in serum lipid profile -- DUR-928 was well tolerated with no significant adverse events -- Promising data support further development of DUR-928 in NASH

A medical device company in Washington State has developed a process that will breathe life into and provide hope to those battling the Coronavirus.

Newly-completed series of patient guidelines from National Comprehensive Cancer Network shares expert advice with patients and caregivers on treatment and prevention for most common head and neck cancers.

Cerus Corporation (Nasdaq:CERS) announced today that the Company has submitted a pre-market approval supplement (PMA-S) to the FDA for a pathogen reduced cryoprecipitated fibrinogen complex with 5-day post thaw storage. This product was previously granted FDA breakthrough device designation based on the potential to improve treatment of mass